Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11810MR)

This product GTTS-WQ11810MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Breast Cancer, Colorectal Cancer (CRC), Non-Small Cell Lung Cancers (NSCLC), Gastric Cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ11810MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11484MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ11598MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ15230MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TAK-079
GTTS-WQ3657MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ8318MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HN-66000
GTTS-WQ8953MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ4240MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ5473MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDB-1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW